Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Gibbons

Showing results (301-310 of 523) with videos related to

Pageof 53
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|July 5, 2023
EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancerGuan-Yu Xiao, Xiaochao Tan, Bertha L Rodriguez, et al.
Frontiers in Immunology|July 14, 2023
Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistanceB Leticia Rodriguez, Limo Chen, Yanli Li, et al.
The Journal of Clinical Investigation|August 16, 2018
The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA networkXiaochao Tan, Priyam Banerjee, Xin Liu, et al.
The Journal of Clinical Investigation|January 12, 2018
The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA networkXiaochao Tan, Priyam Banerjee, Xin Liu, et al.
Cancer Research|May 12, 2017
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or OlaparibTriparna Sen, Pan Tong, C Allison Stewart, et al.
Arxiv|December 25, 2025
From Classical Machine Learning to Emerging Foundation Models: Review on Multimodal Data Integration for Cancer ResearchAmgad Muneer, Muhammad Waqas, Maliazurina B Saad, et al.
Science Translational Medicine|March 15, 2019
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanismDavid H Peng, Samrat T Kundu, Jared J Fradette, et al.
ESMO Open|January 22, 2026
Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1C Vaklavas, M Oliveira, A C Armstrong, et al.
Nature Communications|November 14, 2019
ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancerRoxsan Manshouri, Etienne Coyaud, Samrat T Kundu, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 5, 2020
Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell CarcinomaJose A Monteiro de Oliveira Novaes, Taghreed Hirz, Irene Guijarro, et al.
Pageof 53

Showing results (301-310 of 523) with videos related to

Sort By:
Pageof 53
Proceedings of the National Academy of Sciences of the United States of America|July 5, 2023
EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancerGuan-Yu Xiao, Xiaochao Tan, Bertha L Rodriguez, et al.
Frontiers in Immunology|July 14, 2023
Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistanceB Leticia Rodriguez, Limo Chen, Yanli Li, et al.
The Journal of Clinical Investigation|August 16, 2018
The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA networkXiaochao Tan, Priyam Banerjee, Xin Liu, et al.
The Journal of Clinical Investigation|January 12, 2018
The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA networkXiaochao Tan, Priyam Banerjee, Xin Liu, et al.
Cancer Research|May 12, 2017
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or OlaparibTriparna Sen, Pan Tong, C Allison Stewart, et al.
Arxiv|December 25, 2025
From Classical Machine Learning to Emerging Foundation Models: Review on Multimodal Data Integration for Cancer ResearchAmgad Muneer, Muhammad Waqas, Maliazurina B Saad, et al.
Science Translational Medicine|March 15, 2019
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanismDavid H Peng, Samrat T Kundu, Jared J Fradette, et al.
ESMO Open|January 22, 2026
Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1C Vaklavas, M Oliveira, A C Armstrong, et al.
Nature Communications|November 14, 2019
ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancerRoxsan Manshouri, Etienne Coyaud, Samrat T Kundu, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 5, 2020
Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell CarcinomaJose A Monteiro de Oliveira Novaes, Taghreed Hirz, Irene Guijarro, et al.
Pageof 53